# The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

> **NCT04909866** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** TACE+Lenvatininb+Camrelizumab

## Key facts

- **NCT ID:** NCT04909866
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909866, "The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04909866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*